Suppr超能文献

阿赫迈德青光眼引流阀在新生血管性青光眼中的应用(一篇美国眼科学会论文)

The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).

作者信息

Netland Peter A

机构信息

Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, USA.

出版信息

Trans Am Ophthalmol Soc. 2009 Dec;107:325-42.

Abstract

PURPOSE

To evaluate the results of Ahmed glaucoma valve surgery in neovascular glaucoma and control patients.

METHODS

In this retrospective comparative study, we reviewed 76 eyes of 76 patients, comparing the surgical outcomes in control patients (N=38) to matched neovascular glaucoma patients (N=38). Success was defined as intraocular pressure (IOP) > or =6 mm Hg and < or =21 mm Hg, without further glaucoma surgery, and without loss of light perception.

RESULTS

Average follow-up for control and neovascular glaucoma patients was 18.4 and 17.4 months, respectively (P = .550). At last follow-up, mean IOP was 16.2 +/- 5.2 mm Hg and 15.5 +/- 12.5 mm Hg (P = .115) in control and neovascular glaucoma patients, respectively. Life-table analysis showed a significantly lower success for neovascular glaucoma patients compared with controls (P = .0096), with success at 1 year of 89.2% and 73.1%, at 2 years of 81.8% and 61.9%, and at 5 years of 81.8% and 20.6% for control and neovascular glaucoma eyes, respectively. Cox proportional hazards regression analysis showed neovascular glaucoma as a risk factor for surgical failure (odds ratio, 5.384, 95% CI, 1.22-23.84, P = .027). Although IOP control and complications were comparable between the two groups, visual outcomes were worse in neovascular glaucoma patients, with 9 eyes (23.7%) with neovascular glaucoma compared with no controls losing light perception vision (P = .002). The majority with loss of vision (5 of 9) had successful control of IOP during the postoperative period.

CONCLUSION

Neovascular glaucoma patients have greater risk of surgical failure after Ahmed glaucoma valve surgery compared with controls. Despite improved mean IOP with drainage implants, visual outcomes may be poor, possibly due to progression of underlying disease.

摘要

目的

评估艾哈迈德青光眼引流阀手术治疗新生血管性青光眼及对照患者的效果。

方法

在这项回顾性对照研究中,我们对76例患者的76只眼进行了回顾,比较了对照患者(N = 38)与配对的新生血管性青光眼患者(N = 38)的手术结果。成功定义为眼压(IOP)≥6 mmHg且≤21 mmHg,无需进一步行青光眼手术,且无光感丧失。

结果

对照患者和新生血管性青光眼患者的平均随访时间分别为18.4个月和17.4个月(P = 0.550)。在最后一次随访时,对照患者和新生血管性青光眼患者的平均眼压分别为16.2±5.2 mmHg和15.5±12.5 mmHg(P = 0.115)。寿命表分析显示,新生血管性青光眼患者的成功率显著低于对照组(P = 0.0096),对照眼和新生血管性青光眼眼在1年时的成功率分别为89.2%和73.1%,2年时分别为81.8%和61.9%,5年时分别为81.8%和20.6%。Cox比例风险回归分析显示新生血管性青光眼是手术失败的危险因素(比值比,5.384,95%可信区间,1.22 - 23.84,P = 0.027)。虽然两组之间的眼压控制和并发症相当,但新生血管性青光眼患者的视力预后较差,9例(23.7%)新生血管性青光眼患者无光感,而对照组无此情况(P = 0.002)。大多数视力丧失患者(9例中的5例)在术后眼压得到了成功控制。

结论

与对照组相比,新生血管性青光眼患者在接受艾哈迈德青光眼引流阀手术后手术失败的风险更高。尽管引流植入物使平均眼压有所改善,但视力预后可能较差,这可能是由于潜在疾病的进展所致。

相似文献

1
The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).
Trans Am Ophthalmol Soc. 2009 Dec;107:325-42.
3
The Ahmed Glaucoma Valve in patients with and without neovascular glaucoma.
J Glaucoma. 2010 Dec;19(9):581-6. doi: 10.1097/IJG.0b013e3181ca7f7f.
5
Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma.
Int J Med Sci. 2019 Sep 20;16(10):1371-1376. doi: 10.7150/ijms.35267. eCollection 2019.
8
Ahmed Glaucoma Valve implantation in African American and white patients.
Arch Ophthalmol. 2006 Jun;124(6):800-6. doi: 10.1001/archopht.124.6.800.
9
Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma.
Semin Ophthalmol. 2018;33(5):606-612. doi: 10.1080/08820538.2017.1375123. Epub 2017 Oct 9.
10
Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant.
Ophthalmology. 2008 Jul;115(7):1141-7. doi: 10.1016/j.ophtha.2007.10.034. Epub 2007 Dec 27.

引用本文的文献

1
Intermediate-term outcomes of Ahmed glaucoma valve implantation in glaucoma patients.
BMC Ophthalmol. 2025 Aug 19;25(1):474. doi: 10.1186/s12886-025-04310-6.
2
Ahmed Glaucoma Valve Implantation in Jordan: Indications and Complications.
Clin Ophthalmol. 2024 Dec 4;18:3581-3590. doi: 10.2147/OPTH.S496586. eCollection 2024.
4
Baerveldt glaucoma implant with Supramid ripcord stent in neovascular glaucoma: a case series.
Int J Ophthalmol. 2024 Feb 18;17(2):265-271. doi: 10.18240/ijo.2024.02.06. eCollection 2024.
6
Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma.
J Curr Glaucoma Pract. 2023 Apr-Jun;17(2):91-97. doi: 10.5005/jp-journals-10078-1406.
7
Etiology, pathogenesis, and diagnosis of neovascular glaucoma.
Int J Ophthalmol. 2022 Jun 18;15(6):1005-1010. doi: 10.18240/ijo.2022.06.20. eCollection 2022.
8
Can trainees perform Ahmed glaucoma valve surgery as effectively as attendings?
Oman J Ophthalmol. 2022 Mar 2;15(1):31-35. doi: 10.4103/ojo.ojo_412_20. eCollection 2022 Jan-Apr.
9
Sociodemographic and Economic Factors in Outcomes of Tube Shunts for Neovascular Glaucoma.
J Curr Glaucoma Pract. 2021 May-Aug;15(2):70-77. doi: 10.5005/jp-journals-10078-1303.

本文引用的文献

1
Ahmed glaucoma valve surgical outcomes in eyes with and without silicone oil endotamponade.
J Glaucoma. 2009 Apr-May;18(4):325-30. doi: 10.1097/IJG.0b013e318182ede3.
3
Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Adv Ther. 2009 Feb;26(2):208-16. doi: 10.1007/s12325-009-0001-1. Epub 2009 Feb 20.
4
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up.
Br J Clin Pharmacol. 2008 Nov;66(5):667-73. doi: 10.1111/j.1365-2125.2008.03278.x.
5
Intermediate-term outcome and success of superior versus inferior Ahmed Glaucoma Valve implantation.
J Glaucoma. 2008 Oct-Nov;17(7):584-90. doi: 10.1097/IJG.0b013e31816299bc.
7
Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes.
Am J Ophthalmol. 2008 Aug;146(2):276-284. doi: 10.1016/j.ajo.2008.04.008. Epub 2008 Jun 6.
8
Aqueous shunts in glaucoma: a report by the American Academy of Ophthalmology.
Ophthalmology. 2008 Jun;115(6):1089-98. doi: 10.1016/j.ophtha.2008.03.031.
10
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验